XTLB (XTL Biopharmaceuticals Ltd.) Enterprise Value-to-Revenue Coefficient

XTL Biopharmaceuticals focuses on proprietary molecules to combat autoimmune pathologies, where success depends on testing. The company's environmental strategy is based on "green chemistry" for wastewater treatment. A stable R&D core ensures the preservation of key competencies. This EV/Sales valuation chart on GURU.Markets reflects the price-to-sales dynamics, with the 0.00 metric serving as the target level.
XTL Bio - analytical breakdowns and key metrics (XTLB)

This indicator measures the aggregate value of assets and liabilities relative to annual turnover, allowing investors to filter out market noise and assess the real value of the business without the influence of debt load. Analyzing the enterprise value-to-revenue ratio helps determine the extent to which the market currently prices in the success of the XTL Biopharmaceuticals (XTLB) strategy of acquiring late-stage developments to mitigate biotech risks.